51. Prognostic value of day 14 blast percentage and the absolute blast index in bone marrow of children with acute lymphoblastic leukemia.
- Author
-
Visser JH, Wessels G, Hesseling PB, Louw I, Oberholster E, and Mansvelt EP
- Subjects
- Adolescent, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Asparaginase administration & dosage, Biopsy, Needle, Child, Child, Preschool, Cyclophosphamide administration & dosage, Cytarabine administration & dosage, Daunorubicin administration & dosage, Disease-Free Survival, Ethnicity, Female, Follow-Up Studies, Humans, Infant, Male, Mercaptopurine administration & dosage, Methotrexate administration & dosage, Precursor Cell Lymphoblastic Leukemia-Lymphoma blood, Precursor Cell Lymphoblastic Leukemia-Lymphoma mortality, Predictive Value of Tests, Prednisone administration & dosage, Prognosis, Recurrence, Risk Assessment, South Africa, Survival Rate, Time Factors, Vincristine administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Blast Crisis pathology, Bone Marrow pathology, Precursor Cell Lymphoblastic Leukemia-Lymphoma drug therapy, Precursor Cell Lymphoblastic Leukemia-Lymphoma pathology
- Abstract
The product of the percentage blasts on the bone marrow aspirate (BMA) and the biopsy cellularity has been termed the "absolute blast index aspirate" (ABI-aspirate) and is used to measure disease response on day 7 of induction therapy. The authors compared the event-free survival (EFS) in high-risk and standard-risk patients as identified by the ABI-aspirate and the BMA percentage blasts on day 14 of induction therapy. Both indices identified high-risk cases. EFS of patients categorized as high-risk by these 2 methods and the high-risk criteria used by the authors' service (WCC of > 20 x 10(9)/L, age < 2 and > 8 years and a peripheral blood blast count of > 1.0 x 10(9)/L on day 8 of induction) did not differ. There was concordance between patients identified as high risk by all 3 methods. The results confirmed the prognostic value of the ABI-aspirate and the BMA percentage blasts on day 14 of induction therapy, but these methods were not superior to the high-risk criteria currently in use.
- Published
- 2001
- Full Text
- View/download PDF